Market Overview

Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Related TEVA
Benzinga's Top Upgrades, Downgrades For June 16, 2017
The Market In 5 Minutes
The Vetr community has downgraded $TEVA to 2.5-Stars (Vetr)
Related NVS
Regeneron (REGN) Stock on Fire: What's Behind the Surge?
How Altimmune Is Trying To Get Ahead Of A Potentially Fatal 'Flu Pandemic'
The Vetr community has downgraded $NVS to 2.5-Stars (Vetr)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis (NYSE: NVS) on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI^® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.

Posted-In: News FDA


Related Articles (TEVA + NVS)

View Comments and Join the Discussion!